Applications of ctDNA in lung cancer: informing treatment approaches, MRD and screening

Miguel Garcia-Pardo, MD, Princess Margaret Cancer Center, Toronto, Canada, reflects on the use of circulating tumor DNA (ctDNA) approaches in lung cancer, initially to identify targetable mutations for which there are treatment approaches, and now for minimal disease monitoring (MRD), screening and identifying mechanisms of resistance. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Be the first to comment